

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																						
<p>D'Alonzo et al. 2011 A randomized, double blind, placebo controlled clinical trial of the preoperative use of ketamine for reducing inflammation and pain after thoracic surgery. J Anesth (2011) 25:672-678</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age >18 yrs <p>exclusion criteria</p> <ul style="list-style-type: none"> - age <18 yrs - recent myocardial infarction (within 6 months) - history of psychotic disorder - uncontrolled hypertension - allergy to ketamine - acute intracranial process - evidence of uncontrolled intracranial or intraocular hypertension <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>61±12</td> <td>66±10</td> <td>0.08</td> </tr> <tr> <td>sex (f/m)</td> <td>9/11</td> <td>8/12</td> <td>0.75</td> </tr> <tr> <td>weight (kg)</td> <td>81±19</td> <td>82±18</td> <td>0.41</td> </tr> <tr> <td>height (cm)</td> <td>170±8</td> <td>171±9</td> <td>0.43</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 41 <u>randomised in:</u> group K: 21 group C: 20 <u>excluded:</u> 1 <u>analysed:</u> 40 <u>follow-up:</u> 0, 4, 24 h and discharge</p>		K	C	p	age (yrs)	61±12	66±10	0.08	sex (f/m)	9/11	8/12	0.75	weight (kg)	81±19	82±18	0.41	height (cm)	170±8	171±9	0.43	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group ketamine (K): IV ketamine, 0.5 mg/kg before surgery - group placebo (C): equivalent IV volume of normal saline <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - IV anaesthetic was a combination of propofol, dexmedetomidine and remifentanyl <p>supplemental analgesia</p> <ul style="list-style-type: none"> - 95% of group C and 80% of group K received epidural analgesia - 55% of group K and 70% of group C received an IV anaesthetic - ketorolac was given, either intraop or within the first POD, to 50% of group C and 60% of group K 	<p>postoperative pain [VAS]: mean (95% CI) VAS 0-10, mean and SD</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>baseline</td> <td>0.30±0.73</td> <td>0.35±1.35</td> <td>0.44</td> </tr> <tr> <td>4 h</td> <td>3.8±2.1</td> <td>3.1±2.8</td> <td>0.20</td> </tr> <tr> <td>24 h</td> <td>2.6±2.2</td> <td>2.8±2.1</td> <td>0.20</td> </tr> </tbody> </table> <p>at discharge</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td></td> <td>1.8±2.5</td> <td>1.1±1.8</td> <td>0.15</td> </tr> </tbody> </table> <p>IL-6 plasma levels pg/mL: (mean±SD)</p> <ul style="list-style-type: none"> - were significantly elevated postop, but levels in group K (245±287 pg/mL) compared with levels group C (269±210 pg/mL) did not differ significantly <p>CRP levels at 24 h mg/dL: (mean±SD)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> </tr> </thead> <tbody> <tr> <td></td> <td>8.8±4.5</td> <td>9.3±5.6</td> </tr> </tbody> </table> <ul style="list-style-type: none"> - were increased compared to preop levels, but they were not significantly affected by ketamine administration 		K	C	p	baseline	0.30±0.73	0.35±1.35	0.44	4 h	3.8±2.1	3.1±2.8	0.20	24 h	2.6±2.2	2.8±2.1	0.20		K	C	p		1.8±2.5	1.1±1.8	0.15		K	C		8.8±4.5	9.3±5.6	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - precise details of the interventions intended for each group and how and when they were actually administered were not reported - method used to implement the random allocation sequence not reported <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"These findings suggest that the routine use of a single dose of ketamine prior to chest wall incision is not effective at reducing pain or inflammation in thoracic surgery patients at 24 h postop."</p>				
	K	C	p																																																							
age (yrs)	61±12	66±10	0.08																																																							
sex (f/m)	9/11	8/12	0.75																																																							
weight (kg)	81±19	82±18	0.41																																																							
height (cm)	170±8	171±9	0.43																																																							
	K	C	p																																																							
baseline	0.30±0.73	0.35±1.35	0.44																																																							
4 h	3.8±2.1	3.1±2.8	0.20																																																							
24 h	2.6±2.2	2.8±2.1	0.20																																																							
	K	C	p																																																							
	1.8±2.5	1.1±1.8	0.15																																																							
	K	C																																																								
	8.8±4.5	9.3±5.6																																																								
<p>Fiorelli et al. 2015 Is pre-emptive administration of ketamine a significant adjunction to IV morphine analgesia for controlling postoperative pain? A randomized, double-blind, placebo-controlled clinical trial. Interact Cardiovasc Thorac Surg. 2015;21(3):284-90.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age >18 yrs - ASA physical status I-III <p>exclusion criteria</p> <ul style="list-style-type: none"> - allergy to ketamine - ASA physical status >III - previous thoracotomy or lung resection - psychological disease that may affect ability to report pain - participation in other similar clinical studies - lack of written, informed consent <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>Male</td> <td>23</td> <td>28</td> <td>0.7</td> </tr> <tr> <td>age (yrs)</td> <td>59.5±15.3</td> <td>58.6±17.4</td> <td>0.7</td> </tr> <tr> <td>weight (kg)</td> <td>79.8±10.9</td> <td>77.9±9.7</td> <td>0.5</td> </tr> <tr> <td>Charlson comorbidity index</td> <td>1.2±3.9</td> <td>1.3±1.4</td> <td>0.6</td> </tr> </tbody> </table> <p>ASA classification</p> <table border="1"> <thead> <tr> <th>ASA class</th> <th>K (n)</th> <th>C (n)</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>ASA I</td> <td>26 (68%)</td> <td>29 (78%)</td> <td>1.0</td> </tr> <tr> <td>ASA II</td> <td>11 (29%)</td> <td>8 (22%)</td> <td>0.5</td> </tr> <tr> <td>ASA III</td> <td>1 (3%)</td> <td>0</td> <td>1.0</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 80 <u>randomised in:</u> group K: 38 group C: 37 <u>excluded:</u> 5 <u>analysed:</u> group K: 38 group C: 37 <u>follow-up:</u> 6, 12, 24, 36, 48 h postop</p>		K	C	p	Male	23	28	0.7	age (yrs)	59.5±15.3	58.6±17.4	0.7	weight (kg)	79.8±10.9	77.9±9.7	0.5	Charlson comorbidity index	1.2±3.9	1.3±1.4	0.6	ASA class	K (n)	C (n)	p	ASA I	26 (68%)	29 (78%)	1.0	ASA II	11 (29%)	8 (22%)	0.5	ASA III	1 (3%)	0	1.0	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group K (ketamine): Five min before skin incision, bolus dose of ketamine 1 mg/kg IV - group C (control): same protocol with placebo <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - fentanyl at induction then sufentanyl <p>postoperative analgesia</p> <ul style="list-style-type: none"> - SC morphine 10 mg, 30 min before the end of the intervention - IV ketorolac 30 mg and IV paracetamol 1000 mg on waking, then IV morphine PCA, 1 mg/7 min - rescue analgesics were administered according to a standardised institutional protocol (specifics not reported) 	<p>postoperative pain [VAS 0-10]: mean±SD</p> <table border="1"> <thead> <tr> <th>h</th> <th>K</th> <th>C</th> </tr> </thead> <tbody> <tr> <td>6</td> <td>4.9±0.8</td> <td>5.7±0.4</td> </tr> <tr> <td>12</td> <td>4.4±0.5</td> <td>5.3±0.4</td> </tr> <tr> <td>24</td> <td>4.1±0.5</td> <td>4.8±0.6</td> </tr> <tr> <td>36</td> <td>3.7±0.6</td> <td>4.3±0.4</td> </tr> <tr> <td>48</td> <td>2.7±0.6</td> <td>3.3±0.4</td> </tr> </tbody> </table> <ul style="list-style-type: none"> - VAS scores were significantly lower in group K compared with group C at all time points (p=0.01) <p>morphine consumption</p> <ul style="list-style-type: none"> - the consumption of morphine was lower in group K than in group C at all study time points (p<0.001) <p>adverse effects/ events:</p> <ul style="list-style-type: none"> - no cases reported in either group 	h	K	C	6	4.9±0.8	5.7±0.4	12	4.4±0.5	5.3±0.4	24	4.1±0.5	4.8±0.6	36	3.7±0.6	4.3±0.4	48	2.7±0.6	3.3±0.4	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - no details of who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"The administration of ketamine before surgery may be an effective adjunct to IV morphine analgesia in acute post-thoracotomy pain management."</p>
	K	C	p																																																							
Male	23	28	0.7																																																							
age (yrs)	59.5±15.3	58.6±17.4	0.7																																																							
weight (kg)	79.8±10.9	77.9±9.7	0.5																																																							
Charlson comorbidity index	1.2±3.9	1.3±1.4	0.6																																																							
ASA class	K (n)	C (n)	p																																																							
ASA I	26 (68%)	29 (78%)	1.0																																																							
ASA II	11 (29%)	8 (22%)	0.5																																																							
ASA III	1 (3%)	0	1.0																																																							
h	K	C																																																								
6	4.9±0.8	5.7±0.4																																																								
12	4.4±0.5	5.3±0.4																																																								
24	4.1±0.5	4.8±0.6																																																								
36	3.7±0.6	4.3±0.4																																																								
48	2.7±0.6	3.3±0.4																																																								
<p>Argiriadou et al. 2011</p>	<p>inclusion criteria</p>	<p>intervention prior to anaesthesia</p>	<p>postoperative pain [VAS 0-10]:</p>	<p>methodological shortcomings</p>																																																						

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																								
<p>Intraoperative infusion of S(+)-ketamine enhances post-thoracotomy pain control compared with perioperative parecoxib when used in conjunction with thoracic paravertebral ropivacaine infusion J Cardiothorac Vasc Anesth. 2011;25(3):455–61.</p>	<p>- not reported</p> <p>exclusion criteria</p> <ul style="list-style-type: none"> - any contraindications to subpleural analgesia - neuropathies - neurologic and psychiatric disorders; - allergy to ropivacaine, ketamine, parecoxib or morphine - contraindications to (NSAIDs) - history of severe cardiovascular, cerebrovascular, renal, coagulatory, hematologic or hepatic disease, - alcohol or drug abuse - chronic pain - use of other treatments likely to affect response to analgesia <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>C</th> <th>K</th> <th>P</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>59±11</td> <td>52±17</td> <td>61±10</td> </tr> <tr> <td>weight (kg)</td> <td>75±12</td> <td>77±11</td> <td>79±14</td> </tr> <tr> <td>sex (m/f)</td> <td>21/5</td> <td>21/6</td> <td>21/6</td> </tr> <tr> <td>ASA physical status I/II/III (n)</td> <td>8/14/4</td> <td>9/13/5</td> <td>10/13/4</td> </tr> </tbody> </table> <p>patient flow and follow up: total patient number included: 80 <u>randomised in:</u> group C: 26 group K: 27 group P: 27 <u>excluded:</u> 3 <u>analysed:</u> 80 <u>follow-up:</u> 4, 12, 24, 48 h</p>		C	K	P	age (yrs)	59±11	52±17	61±10	weight (kg)	75±12	77±11	79±14	sex (m/f)	21/5	21/6	21/6	ASA physical status I/II/III (n)	8/14/4	9/13/5	10/13/4	<p>group K (ketamine):</p> <ul style="list-style-type: none"> - IV bolus ketamine 0.5 mg/kg after anaesthesia induction and before surgical incision - continuous intraop IV infusion of ketamine 400 µg/kg/h stopped 20 mins before the end of surgery <p>group P (parecoxib): IV infusion of parecoxib, 40 mg, 20 mins before extubation and 12 h after the procedure</p> <p>group C (control): paravertebral ropivacaine only</p> <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - fentanyl at induction, then remifentanyl - all patients received a subpleural paravertebral infusion bolus of 10 mL 0.6% ropivacaine then continuous infusion of 0.6% ropivacaine at 0.1 mL/kg/h for 48 h <p>at the end of surgery</p> <ul style="list-style-type: none"> - at the beginning of chest closure, all patients received 0.1 mg/kg of IV morphine <p>postoperative analgesia</p> <ul style="list-style-type: none"> - IV PCA morphine postop 1mg/7min - continuous infusion of 0.6% ropivacaine at 0.1 mL/kg/h for 48 h after surgery <p>rescue analgesics</p> <ul style="list-style-type: none"> - if VAS >5, initially suppositories with 1 g paracetamol and 30 mg codeine/6 h - in case of pain persistence, the IV PCA pump was increased 	<ul style="list-style-type: none"> - group K: lower pain scores at rest, movement, coughing than those receiving placebo at 4, 12, 24, and 48 h after surgery (p<0.05) - group P: less pain at rest, movement compared with those with placebo at 12, 24, and 48 h after surgery (p<0.05) - 24 and 48 h after thoracotomy, S(+)-ketamine was associated with less pain than parecoxib (p<0.05) <p>supplementary analgesia</p> <ul style="list-style-type: none"> - no patient required additional analgesics <p>total dosage of morphine in 48 h (mg)</p> <ul style="list-style-type: none"> - consumption of morphine via PCA pump was lower in group K than group C at all study time points during the first 48 h postop (p<0.05) - morphine requirements were not significantly different between group P and group C <ul style="list-style-type: none"> - cumulative 48-h morphine requirements were less in group K compared with groups C and P (p<0.05). 	<ul style="list-style-type: none"> - method used to implement the random allocation sequence not reported - not reported whether the sequence was adequately concealed until interventions were assigned - didn't state who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"Postoperative paravertebral ropivacaine combined with intraoperative S(+)-ketamine provided better early postoperative pain relief than ropivacaine and perioperative parecoxib or ropivacaine alone."</p>																																																																				
	C	K	P																																																																																									
age (yrs)	59±11	52±17	61±10																																																																																									
weight (kg)	75±12	77±11	79±14																																																																																									
sex (m/f)	21/5	21/6	21/6																																																																																									
ASA physical status I/II/III (n)	8/14/4	9/13/5	10/13/4																																																																																									
<p>Joseph et al. 2012</p> <p>Is there any benefit to adding IV ketamine to patient-controlled epidural analgesia after thoracic surgery? A randomized double-blind study</p> <p>Eur J Cardiothorac Surg. 2012;42(4):e58-65.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age ≥18 yrs <p>exclusion criteria</p> <ul style="list-style-type: none"> - contraindication to epidural puncture - contraindication to epidural analgesia - contraindication to NSAIDs/nefopam - unable to understand the protocol or to give reliable pain score (psychiatric disease) - history of drug or alcohol abuse - chronic pain or patients taking concomitant analgesic treatments <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>age (yr):</td> <td>60 (24–80)</td> <td>60 (31–79)</td> <td>0.959</td> </tr> <tr> <td>Men/women</td> <td>14/16 (47/53)</td> <td>14/16 (47/53)</td> <td>1.0</td> </tr> <tr> <td>ASA score</td> <td></td> <td></td> <td></td> </tr> <tr> <td>ASA 1</td> <td>10 (33)</td> <td>11 (37)</td> <td>0.787</td> </tr> <tr> <td>ASA 2–3</td> <td>20 (67)</td> <td>19 (63)</td> <td></td> </tr> <tr> <td>NYHA score</td> <td></td> <td></td> <td></td> </tr> <tr> <td>NYHA 1</td> <td>20 (67)</td> <td>22 (73)</td> <td>0.583</td> </tr> <tr> <td>NYHA 2–3</td> <td>10 (33)</td> <td>8 (27)</td> <td></td> </tr> <tr> <td>BMI (kg/m²)</td> <td>25 (18–34)</td> <td>24 (17–30)</td> <td>0.311</td> </tr> </tbody> </table>		K	C	p	age (yr):	60 (24–80)	60 (31–79)	0.959	Men/women	14/16 (47/53)	14/16 (47/53)	1.0	ASA score				ASA 1	10 (33)	11 (37)	0.787	ASA 2–3	20 (67)	19 (63)		NYHA score				NYHA 1	20 (67)	22 (73)	0.583	NYHA 2–3	10 (33)	8 (27)		BMI (kg/m ²)	25 (18–34)	24 (17–30)	0.311	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group K (ketamine): IV ketamine 0.5 mg/kg during anaesthesia induction, intraoperative infusion of 3 µg/kg/min followed by a postoperative infusion of 1.5 µg/kg/min for 48 h postop, starting at the end of the surgery <ul style="list-style-type: none"> - group C (placebo): same protocol with saline <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - remifentanyl - PCEA, started before incision, ropivacaine (1.5 mg/mL) + sufentanil (0.4 µg/mL) <p>postoperative analgesia</p> <ul style="list-style-type: none"> - PCEA started before incision and up to 48 h postop, ropivacaine 1.5 mg/mL + sufentanil 0.4 µg/mL @ 5 mL/h, and 5 mL bolus, lo 30 min - IV paracetamol 1 g/6 h <p>rescue analgesics</p> <ul style="list-style-type: none"> - if NRS>3: - IV nefopam 20 mg/4 h - IV ketoprofen 50–100 mg/8 h (based on patient's weight) - on POD 3, TEA replaced by oral morphine 	<p>postoperative pain [NRS (0-10)]: mean±SD</p> <ul style="list-style-type: none"> - up to 48 h NRS scores were identical at rest and when coughing at any time during these first 48 h (NS) - NRS scores at 1 and 3 months following thoracotomy did not show any significant difference between groups for either NRS score at rest or dynamic: <p>NRS (rest)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>1 month</td> <td>0.9±1.2</td> <td>0.8±1.3</td> <td>0.827</td> </tr> <tr> <td>3 months</td> <td>1.1±2.1</td> <td>0.3±0.7</td> <td>0.385</td> </tr> </tbody> </table> <p>NRS (abduction)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>1 month</td> <td>1.2±1.5</td> <td>1.2±1.4</td> <td>0.909</td> </tr> <tr> <td>3 months</td> <td>1.3±2.3</td> <td>1.1±2.5</td> <td>0.589</td> </tr> </tbody> </table> <p>total dosage of ropivacaine (mL)</p> <ul style="list-style-type: none"> - similar between groups at 12, 24 and 48 h following surgery. NS <p>rescue analgesic consumption at 48 h (mg): median (min-max)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>Ketoprofen</td> <td>50 (0–300)</td> <td>50 (0–250)</td> <td>0.605</td> </tr> <tr> <td>Nefopam</td> <td>60 (0–120)</td> <td>40 (0–140)</td> <td>0.091</td> </tr> </tbody> </table> <p>late analgesic consumption, n (%)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>1 month</td> <td>9/17 (53)</td> <td>5/20 (25)</td> <td>0.081</td> </tr> <tr> <td>3 months</td> <td>6/18 (33)</td> <td>4/19 (21)</td> <td>0.476</td> </tr> </tbody> </table>		K	C	p	1 month	0.9±1.2	0.8±1.3	0.827	3 months	1.1±2.1	0.3±0.7	0.385		K	C	p	1 month	1.2±1.5	1.2±1.4	0.909	3 months	1.3±2.3	1.1±2.5	0.589		K	C	p	Ketoprofen	50 (0–300)	50 (0–250)	0.605	Nefopam	60 (0–120)	40 (0–140)	0.091		K	C	p	1 month	9/17 (53)	5/20 (25)	0.081	3 months	6/18 (33)	4/19 (21)	0.476	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - no information on whether the sequence was adequately concealed until interventions were assigned - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"Ketamine at low dose did not decrease acute or chronic post-thoracotomy pain"</p>
	K	C	p																																																																																									
age (yr):	60 (24–80)	60 (31–79)	0.959																																																																																									
Men/women	14/16 (47/53)	14/16 (47/53)	1.0																																																																																									
ASA score																																																																																												
ASA 1	10 (33)	11 (37)	0.787																																																																																									
ASA 2–3	20 (67)	19 (63)																																																																																										
NYHA score																																																																																												
NYHA 1	20 (67)	22 (73)	0.583																																																																																									
NYHA 2–3	10 (33)	8 (27)																																																																																										
BMI (kg/m ²)	25 (18–34)	24 (17–30)	0.311																																																																																									
	K	C	p																																																																																									
1 month	0.9±1.2	0.8±1.3	0.827																																																																																									
3 months	1.1±2.1	0.3±0.7	0.385																																																																																									
	K	C	p																																																																																									
1 month	1.2±1.5	1.2±1.4	0.909																																																																																									
3 months	1.3±2.3	1.1±2.5	0.589																																																																																									
	K	C	p																																																																																									
Ketoprofen	50 (0–300)	50 (0–250)	0.605																																																																																									
Nefopam	60 (0–120)	40 (0–140)	0.091																																																																																									
	K	C	p																																																																																									
1 month	9/17 (53)	5/20 (25)	0.081																																																																																									
3 months	6/18 (33)	4/19 (21)	0.476																																																																																									

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																
	<p>patient flow and follow up: <u>total patient number included:</u> 60 <u>randomised in:</u> group K: 30 group C: 30 <u>excluded:</u> 13 <u>analysed:</u> - at 48 h: group K: 22 group C: 25 - long term: group K: 18 group C: 19 <u>follow-up:</u> PACU, 12 h, 24 h, 48 h, 1 and 3 months</p>		<p>adverse events- nausea, n (%)</p> <table border="1"> <thead> <tr> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>8 (36)</td> <td>2 (8)</td> <td>0.030</td> </tr> </tbody> </table>	K	C	p	8 (36)	2 (8)	0.030																											
K	C	p																																		
8 (36)	2 (8)	0.030																																		
<p>Yazigi et al. 2012 The effect of low-dose IV ketamine on continuous intercostal analgesia following thoracotomy Ann Card Anaesth. 2012;15(1):32-8.</p>	<p>inclusion criteria - age 20–75 yrs - ASA physical status II–III exclusion criteria - patient refusal - previous chronic thoracic pain - previous neuropathic pain - previous treatment with analgesics (opiates, tricyclic antidepressants or venlafaxin, gabapentin or pregabalin, clonazepam, carbamazepine, NMDA-R blockers) - contraindication to bupivacaine, morphine, paracetamol, nefopam or ketamine - emergency surgery - poor physical status or advanced phase of cancer - predicted use of epidural anaesthesia or paravertebral block demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> </tr> </thead> <tbody> <tr> <td>age (yrs)</td> <td>57.3±11.9</td> <td>56.9±12.5</td> </tr> <tr> <td>sex (f/m)</td> <td>16/14</td> <td>15/15</td> </tr> <tr> <td>weight (kg)</td> <td>71.1±12</td> <td>71.3±14</td> </tr> </tbody> </table> <p>patient flow and follow up: <u>total patient number included:</u> 80 <u>randomised in:</u> group K: 30 group C: 30 <u>excluded:</u> 20 <u>analysed:</u> 60 <u>follow-up:</u> every 6 h for 72 h</p>		K	C	age (yrs)	57.3±11.9	56.9±12.5	sex (f/m)	16/14	15/15	weight (kg)	71.1±12	71.3±14	<p>intervention prior to surgery - group K (ketamine): before skin incision, a bolus dose of ketamine 0.1 mg/kg IV followed by continuous infusion of 0.05 mg/kg/h for 72 h - group C (control): same protocol with placebo mode of anaesthesia - fentanyl at the end of surgery - before skin closure, intercostal nerve block was initiated in all patients with 20 mL of 0.25% bupivacaine through the intercostal catheter postoperative analgesia - infusion of bupivacaine 0.1 mL/kg/h for 72 h - IV paracetamol 1 g/6 h - IV ketoprofen 50 mg/6 h supplemental analgesia - if VAS>40 mm: IV sulphate morphine as rescue analgesia titrated by boluses of 2 mg/5 mins up to max 0.1 mg/kg/6 h</p>	<p>postoperative pain [VAS] at rest and cough in the 1st 72 h: - NS at all time points of the study rescue analgesia: <u>cumulative dose of morphine per patient (mg): mean±SD</u></p> <table border="1"> <thead> <tr> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>17±16</td> <td>12±17</td> <td>0.2</td> </tr> </tbody> </table> <p><u>number of deliveries of morphine per patient (n: median with first and third quartiles)</u></p> <table border="1"> <thead> <tr> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>1[1–2]</td> <td>2[1–3]</td> <td>0.17</td> </tr> </tbody> </table> <p>adverse effects/ events: n</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>vomiting</td> <td>8</td> <td>6</td> <td>0.4</td> </tr> </tbody> </table> <p>- two patients in the ketamine group experienced blurred vision, hallucination, or nightmares during the study period and infusion was stopped.</p>	K	C	p	17±16	12±17	0.2	K	C	p	1[1–2]	2[1–3]	0.17		K	C	p	vomiting	8	6	0.4	<p>methodological shortcomings - not reported whether the sequence was adequately concealed until interventions were assigned - not reported who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups - no details on the flow of participants through each stage. level of evidence: 1 authors' conclusion "Intravenous low-dose ketamine, when combined with continuous intercostal nerve block, did not decrease acute pain scores and supplemental morphine consumption following thoracotomy."</p>
	K	C																																		
age (yrs)	57.3±11.9	56.9±12.5																																		
sex (f/m)	16/14	15/15																																		
weight (kg)	71.1±12	71.3±14																																		
K	C	p																																		
17±16	12±17	0.2																																		
K	C	p																																		
1[1–2]	2[1–3]	0.17																																		
	K	C	p																																	
vomiting	8	6	0.4																																	
<p>Tena et al. 2014 Perioperative epidural or IV ketamine does not improve the</p>	<p>inclusion criteria - age >18 yrs</p>	<p>intervention prior to surgery</p>	<p>postoperative pain [VAS]:</p>	<p>methodological shortcomings</p>																																

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																																																																																																																																																				
<p>effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy</p> <p>Clin J Pain. 2014;30(6):490-500.</p>	<p>exclusion criteria</p> <ul style="list-style-type: none"> - patient refusal - previous chronic pain or chronic analgesic treatment - history of drug addiction or neurological/psychiatric disorder - contraindication to ketamine, ropivacaine, paracetamol, or opiates - contraindication to TEA - emergency surgery <p>demographic data:</p> <table border="1"> <thead> <tr> <th></th> <th>S</th> <th>KIV</th> <th>KEP</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>Age</td> <td>66.5 (9.9)</td> <td>62.9 (9.8)</td> <td>63.4 (11.9)</td> <td>0.242</td> </tr> <tr> <td>sex</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>F</td> <td>11 (31.4)</td> <td>8 (24.2)</td> <td>10 (27.8)</td> <td>0.793</td> </tr> <tr> <td>M</td> <td>24 (68.6)</td> <td>25 (75.8)</td> <td>26 (72.2)</td> <td></td> </tr> <tr> <td>ASA</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>II</td> <td>7 (20)</td> <td>12 (36.4)</td> <td>10 (27.8)</td> <td></td> </tr> <tr> <td>III</td> <td>28 (80)</td> <td>21 (63.6)</td> <td>26 (72.2)</td> <td></td> </tr> </tbody> </table> <p>patient flow and follow up:</p> <p>total patient number included: 125</p> <p>randomised in:</p> <p>group S: 35</p> <p>group KIV: 33</p> <p>group KEP: 36</p> <p>excluded: 21</p> <p>analysed: 104</p> <p>follow-up: 2, 4, 24, 72 h, 7 d, 3 mon, and 6 mons after surgery</p>		S	KIV	KEP	p	Age	66.5 (9.9)	62.9 (9.8)	63.4 (11.9)	0.242	sex					F	11 (31.4)	8 (24.2)	10 (27.8)	0.793	M	24 (68.6)	25 (75.8)	26 (72.2)		ASA					II	7 (20)	12 (36.4)	10 (27.8)		III	28 (80)	21 (63.6)	26 (72.2)		<ul style="list-style-type: none"> - group KIV: IV ketamine 0.5 mg/kg preincisional + 0.25 mg/kg/h for 48 h - group KEP: epidural ketamine 0.5 mg/kg preincisional + 0.25 mg/kg/h for 48 h - group S (saline): preincisional IV and epidural bolus of saline and a postoperative epidural and IV continuous infusion of saline <p>mode of anaesthesia</p> <ul style="list-style-type: none"> - fentanyl, remifentanyl <p>postoperative analgesia</p> <ul style="list-style-type: none"> - TEA started 20 min before skin closure with an 8 mL bolus of 0.2% ropivacaine - PCEA ropivacaine 0.15% + fentanyl 2 mg/mL bolus 2 mL, 5 mL/h; lo 20 min. (+ EP ketamine or saline or IV ketamine according to the study group) <p>supplemental analgesia</p> <ul style="list-style-type: none"> - IV paracetamol 1 g/6 h - IV metamizol 2 g if required <p>rescue analgesia</p> <ul style="list-style-type: none"> - SC methadone as rescue medication after first 48 h 	<ul style="list-style-type: none"> - VAS scores on coughing were significantly lower in both treatment groups (KIV and KEP) at 24 and 72 h, compared with group S - the VAS score at rest only showed a significant difference at 2 h in group KIV compared with group S (p<0.05), although a nonstatistically significant reduction was observed at 24 and 72 h in KIV and KEP compared with group S. - there were no differences between the groups afterwards, at 3 and 6 months <p>postoperative pain (VAS; mean(SD))</p> <table border="1"> <thead> <tr> <th>Time</th> <th>2 h</th> <th>24 h</th> <th>72 h</th> <th>7 d</th> <th>3 mo</th> <th>6 mo</th> </tr> </thead> <tbody> <tr> <td>Group S</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Rest</td> <td>2.49(1.79)</td> <td>2.71(1.67)</td> <td>3.26(2.23)</td> <td>1.83(1.79)</td> <td>1(1.65)</td> <td>1.06(1.11)</td> </tr> <tr> <td>Cough</td> <td>3.57 (1.7)</td> <td>4.43(2.16)</td> <td>3.14(1.63)</td> <td>1.38(1.84)</td> <td>1.22(1.22)</td> <td></td> </tr> <tr> <td>Group KIV</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Rest</td> <td>1.61(1.6)*</td> <td>1.94(1.68)</td> <td>2.55(1.94)</td> <td>1.82(1.69)</td> <td>0.66(1.43)</td> <td>1.2(1.48)</td> </tr> <tr> <td>Cough</td> <td>2.15(1.77)*</td> <td>3.33(1.76)*</td> <td>2.85(1.44)</td> <td>0.91(1.69)</td> <td>1.3(1.64)</td> <td></td> </tr> <tr> <td></td> <td>p=0.0006</td> <td>p=0.0197</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Group KEP</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Rest</td> <td>1.89(1.75)</td> <td>2.08(1.5)</td> <td>2.81(1.65)</td> <td>1.67(1.49)</td> <td>0.58(1.44)</td> <td>0.91(1.14)</td> </tr> <tr> <td>Cough</td> <td>2.33(1.47)*</td> <td>3.31(1.65)*</td> <td>2.78(1.57)</td> <td>0.91(1.88)</td> <td>1(1.34)</td> <td></td> </tr> <tr> <td></td> <td>p=0.0009</td> <td>p=0.0127</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>*Statistically significant compared with group S</p> <p>supplemental analgesia</p> <ul style="list-style-type: none"> - the highest percentage of patients with VAS>1 was observed in group S (31.4% at 6 mo), but there were no significant differences between the other groups <p>other pain outcome</p> <p>Neuropathic Pain Symptom Inventory (NPSI)</p> <ul style="list-style-type: none"> - the maximum score recorded on the NPSI was 30 (range, 0 to 100). - the proportion of patients with an NPSI score >0 at 72 h postsurgery was 85%, 72%, and 86% for groups S, KIV, and KEP, respectively - at 7 days the corresponding values were 71%, 73%, and 83% - at 3 months they were 65%, 46%, and 53%; and at 6 months the figures were 34%, 24%, and 20%. - there were no significant differences over time between the groups <p>number of patients presenting with area of anaesthesia (n (%)) and size of area (cm² mean (SD))</p> <table border="1"> <thead> <tr> <th></th> <th>S</th> <th>KIV</th> <th>KEP</th> </tr> </thead> <tbody> <tr> <td>72 h</td> <td></td> <td></td> <td></td> </tr> <tr> <td>n</td> <td>5(14.3)</td> <td>2(6.1)</td> <td>1(2.8)</td> </tr> <tr> <td>Area</td> <td>5.27(17.11)</td> <td>4.29(21.96)</td> <td>1.53(9.16)</td> </tr> <tr> <td>7d</td> <td></td> <td></td> <td></td> </tr> <tr> <td>n</td> <td>7(20.0)</td> <td>4(12.1)</td> <td>1(2.8)*</td> </tr> <tr> <td></td> <td></td> <td></td> <td>p=0.018</td> </tr> <tr> <td>Area</td> <td>6.79(17.86)</td> <td>3.42(9.82)</td> <td>1.22(7.33)</td> </tr> <tr> <td>3mo</td> <td></td> <td></td> <td></td> </tr> <tr> <td>n</td> <td>12(35.3)</td> <td>7(21.9)</td> <td>6(18.2)</td> </tr> <tr> <td>Area</td> <td>10.99(20.84)</td> <td>7.23(16.95)</td> <td>12.16(32.83)</td> </tr> <tr> <td>6mo</td> <td></td> <td></td> <td></td> </tr> <tr> <td>n</td> <td>8(40.0)</td> <td>3(33.3)</td> <td>4(30.8)</td> </tr> <tr> <td>Area</td> <td>10.11(19.19)</td> <td>11.99(19.96)</td> <td>18.94(36.47)</td> </tr> </tbody> </table> <p>adverse effects/ events:</p> <ul style="list-style-type: none"> - nightmares or psychotomimetic effects were experienced by 9, 4, and 2 patients in the KEP, KIV, and S groups respectively, however these differences were not statistically significant. 	Time	2 h	24 h	72 h	7 d	3 mo	6 mo	Group S							Rest	2.49(1.79)	2.71(1.67)	3.26(2.23)	1.83(1.79)	1(1.65)	1.06(1.11)	Cough	3.57 (1.7)	4.43(2.16)	3.14(1.63)	1.38(1.84)	1.22(1.22)		Group KIV							Rest	1.61(1.6)*	1.94(1.68)	2.55(1.94)	1.82(1.69)	0.66(1.43)	1.2(1.48)	Cough	2.15(1.77)*	3.33(1.76)*	2.85(1.44)	0.91(1.69)	1.3(1.64)			p=0.0006	p=0.0197					Group KEP							Rest	1.89(1.75)	2.08(1.5)	2.81(1.65)	1.67(1.49)	0.58(1.44)	0.91(1.14)	Cough	2.33(1.47)*	3.31(1.65)*	2.78(1.57)	0.91(1.88)	1(1.34)			p=0.0009	p=0.0127						S	KIV	KEP	72 h				n	5(14.3)	2(6.1)	1(2.8)	Area	5.27(17.11)	4.29(21.96)	1.53(9.16)	7d				n	7(20.0)	4(12.1)	1(2.8)*				p=0.018	Area	6.79(17.86)	3.42(9.82)	1.22(7.33)	3mo				n	12(35.3)	7(21.9)	6(18.2)	Area	10.99(20.84)	7.23(16.95)	12.16(32.83)	6mo				n	8(40.0)	3(33.3)	4(30.8)	Area	10.11(19.19)	11.99(19.96)	18.94(36.47)	<ul style="list-style-type: none"> - method used to implement the random allocation sequence was not reported - whether the sequence was adequately concealed until interventions were assigned was not reported - was not revealed who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups <p>level of evidence: 1</p> <p>authors' conclusion</p> <p>"Adding epidural or IV racemic ketamine to TEA after thoracotomy did not lead to any reduction in PPP or allodynia. Epidural administration produced similar plasma ketamine levels to the IV."</p>
	S	KIV	KEP	p																																																																																																																																																																																				
Age	66.5 (9.9)	62.9 (9.8)	63.4 (11.9)	0.242																																																																																																																																																																																				
sex																																																																																																																																																																																								
F	11 (31.4)	8 (24.2)	10 (27.8)	0.793																																																																																																																																																																																				
M	24 (68.6)	25 (75.8)	26 (72.2)																																																																																																																																																																																					
ASA																																																																																																																																																																																								
II	7 (20)	12 (36.4)	10 (27.8)																																																																																																																																																																																					
III	28 (80)	21 (63.6)	26 (72.2)																																																																																																																																																																																					
Time	2 h	24 h	72 h	7 d	3 mo	6 mo																																																																																																																																																																																		
Group S																																																																																																																																																																																								
Rest	2.49(1.79)	2.71(1.67)	3.26(2.23)	1.83(1.79)	1(1.65)	1.06(1.11)																																																																																																																																																																																		
Cough	3.57 (1.7)	4.43(2.16)	3.14(1.63)	1.38(1.84)	1.22(1.22)																																																																																																																																																																																			
Group KIV																																																																																																																																																																																								
Rest	1.61(1.6)*	1.94(1.68)	2.55(1.94)	1.82(1.69)	0.66(1.43)	1.2(1.48)																																																																																																																																																																																		
Cough	2.15(1.77)*	3.33(1.76)*	2.85(1.44)	0.91(1.69)	1.3(1.64)																																																																																																																																																																																			
	p=0.0006	p=0.0197																																																																																																																																																																																						
Group KEP																																																																																																																																																																																								
Rest	1.89(1.75)	2.08(1.5)	2.81(1.65)	1.67(1.49)	0.58(1.44)	0.91(1.14)																																																																																																																																																																																		
Cough	2.33(1.47)*	3.31(1.65)*	2.78(1.57)	0.91(1.88)	1(1.34)																																																																																																																																																																																			
	p=0.0009	p=0.0127																																																																																																																																																																																						
	S	KIV	KEP																																																																																																																																																																																					
72 h																																																																																																																																																																																								
n	5(14.3)	2(6.1)	1(2.8)																																																																																																																																																																																					
Area	5.27(17.11)	4.29(21.96)	1.53(9.16)																																																																																																																																																																																					
7d																																																																																																																																																																																								
n	7(20.0)	4(12.1)	1(2.8)*																																																																																																																																																																																					
			p=0.018																																																																																																																																																																																					
Area	6.79(17.86)	3.42(9.82)	1.22(7.33)																																																																																																																																																																																					
3mo																																																																																																																																																																																								
n	12(35.3)	7(21.9)	6(18.2)																																																																																																																																																																																					
Area	10.99(20.84)	7.23(16.95)	12.16(32.83)																																																																																																																																																																																					
6mo																																																																																																																																																																																								
n	8(40.0)	3(33.3)	4(30.8)																																																																																																																																																																																					
Area	10.11(19.19)	11.99(19.96)	18.94(36.47)																																																																																																																																																																																					
<p>Feltracco et al. 2013</p> <p>Perioperative analgesic efficacy and plasma concentrations of s(+)-ketamine in continuous epidural infusion during thoracic surgery.</p> <p>Anesth Analg. 2013;116(6):1371-5.</p>	<p>inclusion criteria</p> <ul style="list-style-type: none"> - age >18 yrs - BMI <30 kg/m² - ASA physical status I-III <p>exclusion criteria</p> <ul style="list-style-type: none"> - contraindications for epidural analgesia - history of myocardial dysfunction 	<p>intervention prior to anaesthesia</p> <ul style="list-style-type: none"> - group K (ketamine): received epidurally ketamine 0.25 mg/kg/h, during surgery - group C (control): received ropivacaine 0.25% - both epidural infusions started before skin incision and were run at 6 mL/h for the duration of surgical procedure 	<p>postoperative pain [VAS]: median (95% CI)</p> <p>VAS scores were significantly lower in the ketamine group (p<0.0001) and decreased over time in both groups.</p> <p>cumulative fentanyl consumption during surgery (µg), median (95% CI)</p> <table border="1"> <thead> <tr> <th></th> <th>K</th> <th>C</th> <th>p</th> </tr> </thead> <tbody> <tr> <td></td> <td>225.0(29.5-490.0)</td> <td>272.9(99.1- 128.0)</td> <td>0.0032</td> </tr> </tbody> </table>		K	C	p		225.0(29.5-490.0)	272.9(99.1- 128.0)	0.0032	<p>methodological shortcomings</p> <ul style="list-style-type: none"> - no clear definition of primary or secondary outcome measures - method used to implement the random allocation sequence was not reported 																																																																																																																																																																												
	K	C	p																																																																																																																																																																																					
	225.0(29.5-490.0)	272.9(99.1- 128.0)	0.0032																																																																																																																																																																																					

reference	participants' characteristics	intervention group/ control group	outcomes	critical appraisal/ conclusion																																																				
	<p>- systemic organ dysfunction - inability to understand the study protocol</p> <p>demographic data:</p> <table border="0"> <tr> <td>group K</td> <td>group C</td> <td></td> <td>p</td> </tr> <tr> <td>age (yrs)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>61.5 (19–80)</td> <td>65 (24–81)</td> <td>0.1497</td> <td></td> </tr> <tr> <td>sex (m/f)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>18/52</td> <td>19/51</td> <td>0.8480</td> <td></td> </tr> <tr> <td>weight (kg)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>71.5 (46–89)</td> <td>66 (47–100)</td> <td>0.0376</td> <td></td> </tr> <tr> <td>Height (m)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>1.70 (1.48–1.90)</td> <td>1.67(1.48–1.87)</td> <td>0.0058</td> <td></td> </tr> <tr> <td>BMI (kg/m²)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>24.51 (17.21–36.57)</td> <td>24.38 (17.26–34.20)</td> <td>0.9900</td> <td></td> </tr> <tr> <td>Duration of surgery (min)</td> <td></td> <td></td> <td></td> </tr> <tr> <td>182.5 (27–502)</td> <td>180 (65–480)</td> <td>0.8213</td> <td></td> </tr> </table> <p>patient flow and follow up:</p> <p><u>total patient number included:</u> 140</p> <p><u>randomised in:</u> group K: 70 group C: 70</p> <p><u>excluded:</u> not reported</p> <p><u>analysed:</u> 140</p> <p><u>follow-up:</u> 0, 1, 2, 24, 48 h</p>	group K	group C		p	age (yrs)				61.5 (19–80)	65 (24–81)	0.1497		sex (m/f)				18/52	19/51	0.8480		weight (kg)				71.5 (46–89)	66 (47–100)	0.0376		Height (m)				1.70 (1.48–1.90)	1.67(1.48–1.87)	0.0058		BMI (kg/m ²)				24.51 (17.21–36.57)	24.38 (17.26–34.20)	0.9900		Duration of surgery (min)				182.5 (27–502)	180 (65–480)	0.8213		<p>mode of anaesthesia - fentanyl</p> <p>intervention before surgery - TEA started before incision</p> <p>postoperative analgesia - both groups of patients received continuous epidural infusions (5 mL/h) of ropivacaine (0.1%–0.125%) plus fentanyl (2 µg/mL)</p> <p>supplemental analgesia - if VAS>3: single or simultaneous combinations of 2 or 3 analgesics were administered for pain relief, according to medical judgment.</p>	<p>rescue analgesia - far greater use of rescue analgesic drugs, alone or combined, was observed in group C (74.3%) than in the group K (15.7%)</p> <p>adverse effects/ events No patients complained of psychotomimetic effects in the postoperative period</p>	<p>- whether the sequence was adequately concealed until interventions were assigned was not reported</p> <p>- was not revealed who generated the allocation sequence, who enrolled participants, and who assigned the participants to their groups</p> <p>level of evidence: 1</p> <p>authors' conclusion "Epidural infusion of subanaesthetic doses of S(+)-ketamine during thoracic surgery provides better postoperative analgesia than epidural ropivacaine"</p>
group K	group C		p																																																					
age (yrs)																																																								
61.5 (19–80)	65 (24–81)	0.1497																																																						
sex (m/f)																																																								
18/52	19/51	0.8480																																																						
weight (kg)																																																								
71.5 (46–89)	66 (47–100)	0.0376																																																						
Height (m)																																																								
1.70 (1.48–1.90)	1.67(1.48–1.87)	0.0058																																																						
BMI (kg/m ²)																																																								
24.51 (17.21–36.57)	24.38 (17.26–34.20)	0.9900																																																						
Duration of surgery (min)																																																								
182.5 (27–502)	180 (65–480)	0.8213																																																						